anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
NEW MATERIAL:The complex of influenza HANA antigen and a derivative of muramyldipeptide (abbreviated as MDP). EXAMPLE:HANA-B30-MDP complex. USE:An influenza vaccine. It has improved immunogenicity compared with known vaccine as an artificial membrane vaccine like the influenza virus particle, i.e. a virosome vaccine. PREPARATION:Influenza HANA antigen is mixed with an MDP derivative such as the compound of formula (Q is 20-60C synthetic higher fatty acid residue; A is L-alanine, L-serine, etc.; isoGLn is isoglutamine) at a weight ratio of 10/1-1/300 in a phosphate buffer solution. The mixed liquid is solubilized with 0.1-10W/V% surfactant. The surfactant is removed from the solubilized product by dialysis to obtain the objective complex of HANA antigen and MDP derivative.
CD97 is an activation-induced antigen on leucocytes with a seven-span transmembrane (7-TM) region homologous to the secretin receptor superfamily.  However, in contrast to this group of peptide hormone receptors, CD97 has an extended extracellular region with three EGF domains at the N-terminus, two of them with a calcium binding site. Lymphocytes and erythrocytes specifically adhere to CD97-transfected COS cells which is blocked by a monoclonal antibody (mAb) directed to the N-terminal short consensus repeat (SCR) of decay accelerating factor (DAF, CD55), a regulatory protein of the complement cascade. Erythrocytes that lack CD55, obtained from patients with paroxysmal nocturnal hemoglobinuria (PNH) or the CD55- phenotype Inab, failed to adhere to CD97 transfectants. The invention provides methods and means to interfere in the binding of CD97 and CD55. This will be especially useful in xenotransplant medicine where CD55 is used to down regulate the complement activation pathway.
The same internet-based parenting program with weekly parental support from a family guide (psychologist) via a chat function integrated into the program. The addition is three 10-15 minutes long digital/phone meetings between the family guide and the parent.
Cereal grain based products constitute a major part of the daily diet, and wheat is the most important crop for humans representing a source of multiple nutrients, dietary fiber and bioactive compounds, especially if consumed as wholegrain. Depending on its physical and chemicals properties, such as structure of grains, granular size of semolina, quantity and quality of fiber and phytochemicals, amylose/amylopectin ratio, wheat may vehicle protective effects on human health. After the Green Revolution, most of wheat species grown are hybrids, which derive from ancient wheat over the last 100 to 150 years. The main results of this revolution were the development of modern varieties characterized by higher yield, a reduced susceptibility to disease and insects, an increase tolerance to environmental stresses, a homogeneous maturation and a better gluten quality, compared to ancient wheat. At the same time, a decrease in genetic variability as well as a gradual depletion of the nutritional and nutraceutical properties of the wheat occurred. However, over the last years, the increase of diet-related chronic disease led to the nutritional improvement of wheat for ameliorating its health potential. Nowadays, the higher value of whole grains than refined grains is recognized, while the nutritional effects of ancient versus modern grains is still controversial. Generally, ancient species are higher in vitamins, such as folate, niacin and vitamin B6, as well as in minerals such as calcium, iron, magnesium and phosphor compared to modern species, however evidence linked to their real health in vivo effects is still lacking. Therefore, the aim of the present study is to evaluate the nutritional profile of eight breads made with ancient (Triticum heritage varieties) or modern grains on the plasma response of glucose and insulin.
PURPOSE:To enable easy classification and identification of Candida germ with high specificity by using a reagent contg. the antibody (marker) secreted from the hybridoma of anticandida germ antibody producing cells and the cells which can be subcultured in vitro for a long period of time. CONSTITUTION:For example, a mouse or the like is immunized with Candia albicans and anticandida germ antibody producing cells are taken from the pulpar cells thereof. A hybridoma is obtd. from such cells and the cells of the myeloma, etc. that can be subcultured for a long period of time. The antibody secreted by such hybridoma, or the fraction of the antibody or the antibody marked with enzyme, <125>I, fluorescent dye, etc. and fixed or diluted on or an a carrier is used as a reagent. Such reagent is brought into reaction with the liquid to be examined, such as urine or the like, and the activity in marking or the like of the conjugate of the Candida germ and the marked antibody is measured. The easy and exact identification and classification of the germ are thus made possible.
<P>PROBLEM TO BE SOLVED: To provide a method for extracting essence of a bamboo without necessitating a large-scaled apparatus.  <P>SOLUTION: A washed bamboo shoot with its sheath is thrown into a predetermined tank, and water in an amount to hide the bamboo shoot to the very limit is fed and an appropriate glucide as a fermentation accelerator is added. The bamboo shoot is allowed to spontaneously ferment for three to five years. In a second step, the fermented bamboo shoot is pressed to extract the essence thereof and the essence is added to the residual solution followed by filtration to extract the essence of the bamboo shoot. Thus, natural essence of a bamboo shoot, which is relatively easy to collect and transfer while reducing labor necessary for cutting down and transferring a bamboo, is inexpensively manufactured.  <P>COPYRIGHT: (C)2010,JPO&INPIT
This is a prospective randomized controlled study. Patients who meet the inclusion criteria and do not meet the exclusion criteria are recruited for this trial. They will be randomly divided into the control group and the intervention group (A total of 70 subjects, and 35 per group based on calculation of sample size). The in vitro bionic model next to the doctor simulated a medical staff, which is printed via the stereolithographic appearance 3D printing technique following the morphological structure data of human face and airway obtained by processing CT images, will either wear a mask or not, depending on the intervention group (in the intervention group, in vitro model wears personal protective equipment). Before starting the esophagogastroduodenoscopy (EGD) under anesthesia, vitamin B2 saline solution (vitamin B2 dosage determined by the suggested daily nutrient uptake in China) is dripped in their mouths. When the examination is finished, the dosage of facial mucosa deposition and airway inhalation of the in vitro model is quantified as a cumulative droplet mass (μg) over all the exposure time. The deposited droplets are collected by wiping method, and the inhaled droplets are sampled by a solution-based sampler (SKC, U.S.A.). The dosage is detected by the Fluoro Max-4® fluorophotometer (HORIBA, Japan). By comparing and analyzing the results of the two intervention groups, the researchers try to evaluate the risk of exposure under the personal protective equipment and assess the effectiveness of it.
Currently, Brazil has no estimates for quality of life, and/or utilities for ADHD economy analysis. Such data is necessary to calculate the QALYs (Quality Adjusted Life Years). Thus, the investigators will implement the Health Utility Index tool (HUI) to be completed by the patient and/or family, in two moments of an observational study with immediate-release methylphenidate: at baseline and 6th month of treatment. The determination of the QALY as an outcome in the decision analysis is justified because HUI incorporates into a single measure morbidity and mortality. The results of the cost-effectiveness study will assist government agencies in the process of decision making.

To determine the cost-effectiveness of methylphenidate immediate release available in the Brazilian market, the investigators will use a Markov model of decision analysis. The development of the model and analysis of the results will adopt the standards established in the Methodological Guidelines of the Brazilian Ministry of Health, and the perspective will be of the Brazilian National Health System. Medications prices will be obtained through the Board of Market Regulation of Medicines (CMED) at the site of ANVISA (National Health Surveillance Agency). For the treatment strategy that provides greatest cost ratio it will be calculated the incremental cost-effectiveness, compared to the lower cost. To estimate more accurately the impact on life, a Monte Carlo simulation with 10,000 random trials will be conducted.

This is a one treatment group and observational study, with 140 patients, and no controls. Where indicated, it will be suggested the use of 10 mg methylphenidate in a maximum dose of 0.5 mg / kg / day. The total treatment monitoring is 06 (six) months, and patients will be evaluated at baseline, first, third and sixth month. The HUI rating scales will be fulfilled by parents and patients (if \>12 years old only) at baseline and 6th month. The period for inclusion of new patients comprises from 01/01/2011 to 31/12/2013.
The recommended dose is 250 mcg/m2/day administered intravenously over 24 hours or subcutaneously once daily. Continue at the same dose through the period of PBPC collection. The optimal schedule for PBPC collection has not been established. In clinical studies, collection of PBPC was usually begun after 5 days of LEUKINE and performed daily until protocol specified targets were achieved [see Clinical Studies (14)].

If WBC greater than 50,000 cells/mm3, reduce the LEUKINE dose by 50%. Consider other mobilization therapy if adequate numbers of progenitor cells are not collected.
Toxic effects from overdosage of atropine are not uncommon, especially in children. Individual tolerance varies greatly, but these systemic doses are likely to produce the following effects.

A scarlatiniform rash may occur. Atropine may produce fever, particularly in children, through inhibition of heat loss by evaporation. Although large doses of atropine may cause an alarming condition, recovery is usual.

In the treatment of atropine poisoning, respiratory assistance and symptomatic support are indicated.

Pilocarpine is sometimes given but is of limited value.
Formulations have been developed to improve the solubility of corticosteroids such as fluticasone proprionate in a composition designed to achieve localized release of the drug in the small intestine and/or colon. In one embodiment, solid dispersions of fluticasone are prepared wherein the drug is blended with or coated onto a highly water soluble substrate such as nonpareil (sugar beads) then coated with a layer of polymer soluble in small intestinal fluid, then coated with an enteric coating. The inner polymer layer controls release of the drug, and the enteric coating, a pH sensitive polymer that is broken down in the ileum and colon, controls localized release of drug at various sites within the gastrointestinal tract. The multilayer pharmaceutical composition can be in the form of pellets, tablets compressed from pellets or pellets packed into capsules. The release profile of the drug can be manipulated by (1) altering size or shape (i.e., surface area) and solubility of the inert substrate; (2) the ratio of drug to polymer, the polymer composition and solubility, the porosity of the polymer; (3) the drug form (i.e., free base or salt, or which salt); and the thickness and/or surface area of the drug/polymer and/or enteric coating. In a preferred embodiment, the composition is administered orally. This may also be packaged to provide for an escalating or tapering dosage.
BACKGROUND: Integrated-pathy aims to integrate modern medicine with traditional systems via applying the holistic approach of Ayurveda, Yoga, and natural medicine. This is important for addressing the challenges surrounding the delivery of long-term palliative care for chronic ailments including cancer. The prime intent of this study was to substantiate the underlying hypothesis behind the differential and integrative approach having a positive impact on Quality of Life of cancer patients.
STUDY DESIGN: Cross-sectional Observational study.
METHODS: A standardized questionnaire was developed and used, after obtaining written informed consent from patients to assess the impact of Integrated-pathy on patients (n = 103) diagnosed with cancer receiving care at Patanjali Yoggram. The research was carried out over 8 months. All participants received a uniform treatment protocol as prescribed by Patanjali. For the sample size determination and validation, α and 1-β was calculated and for the significance of the pre- and post-treatment QoL ratings, Shapiro wilk test and other descriptive statistics techniques were explored.
RESULTS: A total of 103 patients seeking cancer special-healthcare were interviewed, out of which 39 (37.86%) remained finally based on the inclusion/exclusion criteria with age (25-65 years), types of cancers (Carcinoma and Sarcoma), chemotherapy/radiotherapy received or not, before opting Integrated-pathy. Follow-ups revealed a significant increase in the QoL (17.91%) after receiving the integrated therapy over a course of at least 1 month. Further, a significant reduction in cancer-related pain followed by an increase in QoL index was reported in the patients. Shapiro-wilk test revealed significant pairing (p < 0.001) with validation of the model using test.
CONCLUSIONS: To bolster evidence-based backing for Integrated-pathy, there is a need for clearly delineated clinical indicators that are measurable and trackable over time. Clinical investigators are encouraged to incorporate Integrated-pathy into their proposed interventions and conduct analogous studies to yield sustained advantages in the long run.
Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
Ultrasound screening for hepatocellular carcinoma (HCC) in patients with liver cirrhosis has a poor sensitivity for small tumors. Circulating microRNAs (miRNAs) have been explored as HCC biomarkers, but results are diverging. Here, we evaluate if miRNAs up-regulated in HCC tissue can be detected in plasma and used as screening biomarkers for HCC. In this cross-sectional study, plasma, HCC tissue and surrounding non-tumorous liver tissue were collected from liver resections. Tissue miRNAs were identified and quantitated by RNA-sequencing analysis, and the fold-changes between HCC and surrounding liver tissue were calculated. The miRNAs up-regulated in HCCs were then re-analyzed in plasma from the same patients, and the miRNAs with the highest plasma levels were subsequently measured in plasma from an independent cohort of patients with cirrhosis or HCC. In tissues from 84 resected patients, RNA-sequencing detected 197 differentially expressed miRNAs, 40 of which had a raw count above 200 and were analyzed in plasma from the same cohort. Thirty-one miRNAs were selected for further analysis in 200 patients with HCC or cirrhosis. Of these, eleven miRNAs were significantly increased in HCC as compared to cirrhosis patients. Only miR-93-5p and miR-151a-3p were significantly associated with HCC, with an AUC of 0.662. In comparison, alpha-fetoprotein and des-gamma-carboxy prothrombin yielded an AUC of 0.816, which increased to 0.832 if miR-93-5p and miR-151a-3p were added. When including sex and age, the addition of miR-93-5p and miR-151a-3p did not further improve the AUC (from 0.910 to 0.911). In conclusion, micro-RNAs up-regulated in HCCs are detectable in plasma but have a poor performance as screening biomarkers of HCC.
Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
Ganaxolone, a neuroactive steroid anticonvulsant that modulates both synaptic and extrasynaptic γ-aminobutyric acid type A (GABAA ) receptors, is in development for treatment of status epilepticus (SE) and rare epileptic disorders, and has been approved in the United States for treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients ≥2 years old. This phase 1 study in 36 healthy volunteers evaluated the pharmacokinetics, pharmacodynamics, and safety of intravenous ganaxolone administered as a (i) single bolus, (ii) infusion, and (iii) bolus followed by continuous infusion. After a single bolus over 2 minutes (20 mg) or 5 minutes (10 or 30 mg), ganaxolone was detected in plasma with a median Tmax of 5 minutes, whereas a 60-minute infusion (10 or 30 mg) or a bolus (6 mg over 5 minutes) followed by infusion (20 mg/h) for 4 hours achieved a median Tmax of approximately 1 and 3 hours, respectively. Cmax was dose and administration-time dependent, ranging from 73.8 ng/mL (10 mg over 5 minutes) to 1240 ng/mL (30 mg over 5 minutes). Bolus doses above 10 mg of ganaxolone markedly influenced the bispectral index score with a rapid decline; smaller changes occurred on the Modified Observer's Assessment of Alertness/Sedation scale and in quantitative electroencephalogram. Most adverse events were of mild severity, with 2 events of moderate severity; none were reported as serious. No effects on systemic hemodynamics or respiratory functions were reported. Overall, ganaxolone was generally well tolerated at the doses studied and demonstrated pharmacokinetic and pharmacodynamic properties suitable to treat SE.
We propose to investigate the underlying mechanisms that account for neurobiological dysregulation of HPA axis function in PTSD. Paradoxically, low or normal plasma and urinary cortisol despite high corticotrophin releasing hormone (CRH) levels are a major feature of this disorder. Some investigators report decreased hippocampal volume in patients with PTSD. The mechanisms responsible for these alterations are not known. One possibility is that patients with PTSD have an increased number of glucocorticoid receptors (GR) and/or increased GR sensitivity, causing hyper-suppression of HPA axis. Another possibility is that high CRH levels lead to increased mineralocorticoid receptor (MR) levels and this up-regulation of MR is responsible for the low cortisol secretion seen in PTSD. Elevated CRH levels could also result in reduced hippocampal volume.

In order to evaluate MR and GR function, we will examine the effect of RU486 (Mifepristone; a GR antagonist), spironolactone (Aldactone; an MR antagonist), and placebo, on cortisol and ACTH plasma levels in patients with PTSD, trauma exposed, and non-trauma exposed healthy controls. The extent of increase in cortisol and/or ACTH after administration of antagonists will reflect the inhibition ordinarily imposed by GR and MR. We will also examine subjects' cerebral spinal fluid (CSF), CRH levels, and hippocampal volume. Following this evaluation, patients with PTSD will be treated with paroxetine for 8 weeks. The assessments performed before treatment will then be repeated.

The first aim of the present study is to elucidate the pathophysiology of PTSD through the examination of the roles of GR and MR in maintaining PTSD HPA axis dysregulation. The second aim is to compare CSF CRH levels across groups in an effort to extend previous findings and determine whether CRH levels in PTSD are higher than levels in trauma exposed healthy subjects. The present investigation will also evaluate the relationship between CRH levels in PTSD, MR/GR function, hippocampal volume and hippocampally-mediated cognitive tasks. Finally, we will examine the effects of long-term paroxetine treatment in PTSD on HPA axis function, hippocampal volume, and hippocampally-mediated cognitive tasks.
Some embodiments of the invention comprise a compound of the invention (e.g., a compound of formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the compounds of the invention. Still other embodiments of the invention comprise compositions useful for treating, for example, certain diseases using the compounds of the invention. Some embodiments include methods of administration and treatment using the compounds of the invention (e.g., the compounds of the invention in a composition or in a pharmaceutical composition). Further embodiments include methods for preparing the compounds of the invention. Additional embodiments of the invention are discussed herein.
The application discloses a new application of a small molecular compound, namely an application of the small molecular compound in preparing a medicament for treating glioma, which is used for solving the embarrassing situation of glioma treatment. The application provides application of a compound or pharmaceutically acceptable salt of the compound in preparation of a medicament for treating glioma. The compound is a compound B or a compound A. The structural formula of the compound B is shown as a formula (II). The structural formula of the compound A is shown as the formula (I). The application can be used in glioma treatment and medicine field, and has great application value.
The invention provides a combined concentrated and inactivated vaccine of Newcastle disease and H9 subtype avian influenza, which contains an inactivated Newcastle disease virus LaSota strain, an inactivated H9 subtype avian influenza virus HL strain and an adjuvant. The invention further provides a preparation method of the combined concentrated and inactivated vaccine. According to the combined concentrated and inactivated vaccine provided by the invention, the immunizing dose of the vaccine is reduced to one third of a traditional vaccine, namely, the immunizing dose of the vaccine is reduced from 0.3 ml to 0.1 ml per chick which is 1-5 weeks old, by means of increasing the antigen content in unit volume of the vaccine so that the stress reaction of vaccine immunity to an organism is reduced. Furthermore, the vaccine provided by the invention is applied to chicken with a small age in days so that the application range of the vaccine is widened. In addition, the immunity effect of the vaccine provided by the invention is not reduced on the premise of reducing the dose of the vaccine. Therefore, the combined vaccine of the Newcastle disease and the avian influenza, provided by the invention, has the advantages of small dose of the vaccine, better immune effect, lower cost and longer immune protection period.